Goldman Sachs on AstraZeneca (AZN): 'we are positive on the long-term outlook and like the company's strategy'
Tweet Send to a Friend
Goldman Sachs analyst Rajan Sharma reiterated a Conviction Buy rating and $98.00 price target on AstraZeneca (NASDAQ: AZN).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
